tbuckley/cabot-search huggingface dataset:
Hepatic arterial infusion chemotherapy (HAI) with oxaliplatin (O), 5-fluorouracil (5FU), and folinic acid (FA) in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC): A phase II study
Authors: A. Nicolaou, A. Goerke, M. Sinn, B. Hildebrandt, J. Ricke, M. Pech, P. Podrabsky, U. P. Neumann, B. Dörken, H. Riess
Journal: Journal of Clinical Oncology (2008)

15562 Background: There is no standard chemotherapy for unresectable BTC. The same was true for HCC prior to sorafenib. Both cancers show similar median survival times (8 to 10 months). Because tumour growth in these patients (pts) is often restricted to liver HAI may be effective. Methods: By end of december 2007 20 consecutive pts with a minimal follow up of 28 months and histologically confirmed advanced inoperable HCC (n=11) or BTC (n=9) without relevant distant metastases received HAI with 5FU 600 mg/mq/2h together with FA 170 mg/mq/2h followed by O 85 mg/mq/2h, d1 every 2 weeks using catheters placed interventionally in the a. hepatica via a. femoralis and connected to port chambers until disease progression or port complication. Median age was 66 years (range 43–76). 10 pts (5 BTC/ 5 HCC) prior underwent partial liver resections for their primary cancer. Pts were followed prospectively with regard to port complications, response rate, TTP and OS. Results: Chemotherapy was well tolerated. Median treatment duration was 3.7 months (0.5 - 44.7), 3.7 (0.6 - 22.2) for BTC and 3.7 (0.5 - 44.7) for HCC. End of treatment was due to tumour progression in 10 pts and port complication in 3 pts (1 thrombosis/infection, 1 thrombosis/dislocation and 1 abscess) preceding PD. Median TTP was 5.8 months (0.5 - 44.7), 11.6 (0.6 - 37.8) for BTC and 3.5 (0.5 - 44.7) for HCC. 4 pts developed intra-hepatic progression (3 BTC/ 1 HCC), 3 showed new extra-hepatic metastasis (2/1) and 3 both (1/2). Median OS was 11.7 months (range 0.8 - 44.7+), 16.4 (1.6 - 37.8+) for BTC and 5.4 (0.8 - 44.7+) for HCC. 1y, 2y and 3y-survival was 55% (27.3% HCC, 77.8% BTC), 30% (15, 15) and 15% (10, 5), respectively. Conclusions: Prolonged HAI chemotherapy with oxaliplatin, fluorouracil and folinic acid was feasible and well tolerated. It is a promising treatment approach in pts with BTC restricted to the liver and in HCC when sorafenib is not tolerated. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen, Bayer, Hoffmann-La Roche, Lilly, Merck, Novartis, Pfizer, sanofi-aventis
Interim results of a weekly, metronomic dosing of paclitaxel, oxaliplatin, leucovorin, 5-FU (POLF) in the treatment of metastatic pancreatic cancer (PC)
Authors: B. Chue
Journal: Journal of Clinical Oncology (2007)

15175 Background: Metastatic PC has a dismal prognosis and few effective therapies, resulting in early death and poor quality of life. Weekly “metronomic dosing” of chemotherapy allows for increase dose density, dose intensity, and anti-angiogenic effects, yet affords good tolerability, allowing for a better quality of life and perhaps better efficacy. We report the encouraging interim results of the first nine patients treated twelve weeks with this POLF regimen. Methods: Nine patients ages 35 to 75 with metastatic biopsy proven PC were treated with weekly POLF (P: 60 mg/m 2 , O: 50mg/ m 2 , L: 20 mg/m 2 , F: 425 mg/m 2 ) for twelve weeks. One patient (A.B.) also received intermittent Cetuximab. Glutathione, calcium, and magnesium were used to prevent Oxaliplatin- related neuropathy. Patients were seen weekly. Sequential CA 19–9 levels and CT scans were obtained. Results: After 12 weeks of treatments, 7/9 patients had greater than 50% reduction of CA 19–9 levels (see table ), improvement of cancer-related symptoms and shrinkage of tumor. Patient D.P. had a bilirubin of 27 and patient L.C. had bilirubin of 9.6, both of which normalized with treatment without need for stent placement. Patient A.B. was severely debilitated (ECOG 4) following progression of disease after 2 prior lines of chemotherapy but is alive and well after two years since diagnosis, with ECOG 0. The regimen was well tolerated with only one grade 3 neurotoxicity (L.C.) and one grade 3 diarrhea (B.P.). Median survival has not been reached. Conclusions: Weekly combination of Paclitaxel, Oxaliplatin, Leucovorin, and 5-FU has significant activity against advanced PC with manageable side effects. A Phase II study is opened to enrollment, and we welcome participation. [Table: see text] No significant financial relationships to disclose.
Consistency between K-ras mutation in peripheral blood and matched tumor tissues detected by PCR-RFLP in Chinese patients with advanced NSCLC and its clinical significance analysis
Authors: W. Shuhang, H. Bai, J. Zhao, C. J. Duan, L. Yang, N. M. Wu, J. Z. Wang, Y. Y. Wang, L. M. Zhuo, L. M. Zhuo, J. Wang
Journal: Journal of Clinical Oncology (2009)

8090 Background: To explore the consistency between K-ras mutation in peripheral blood and matched tumor tissues detected by PCR-RFLP and analyze the prognostic effects of K-ras mutation in peripheral blood in Chinese NSCLC patients (pts) treated by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Methods: Plasma free DNA and matched tumor samples were collected from 264 hospitalized pts in Department of Thoracic Oncology, Peking University School of Oncology between Jan 2005 and Feb 2008. K-ras mutations were detected in coden 12 and 13 of exon 1 by PCR-RFLP and then verificated by sequencing. We compared the mutations in plasma samples and matched tumor tissues which determined an association between K-ras mutation status and clinical outcomes. Results: In 264 pts, K-ras mutation rates in codon 12 and 13 of exons 1 in peripheral blood were 11.36% (30/264) and 0.75% (2/264), also 9.84% (26/264) and 1.13% (3/264) in matched tumor tissues, respectively. Consistency of mutation in codon 12 between in tissues and plasma was 94%(248/264) (Kappa=0.686,P&lt;0.001). Among 107 pts who received EGFR-TKIs treatment, the effective rate(RR), progression-free survival (PFS) and median survival time (MST) in pts with K-ras mutation in plasma DNA were 6.7.%, 2.7 months and 20.5 months, respectively, all which were lower than those of pts with wild type K-ras (32.5%, 23.7 months, 31.5 months; P=0.001, P=0.001, P=0.278, respectively). Conclusions: There is a high consistency of K-ras mutation rate between plasma DNA and matched tumor tissues. K-ras mutation in plasma is able to predict both response and PFS of NSCLC pts with EGFR-TKIs treatment. No significant financial relationships to disclose.
Correspondence
Authors: P Whidden, G Howie
Journal: Cardiovascular Research (1997)

w x Ž . The mini-review 1 about Raynaud’s phenomenon RP mentions in passing that passive smoking ‘may be harmful’ to patients with RP. Two cases of RP definitely linked Ž . to second-hand smoking apparently causally have been w x noted in the literature 2 . A striking factor shared in these two cases is that they were both consecutively married to the same heavily smoking man. Also, both women, once they were no longer exposed to his heavy tobacco-smoke Ž . pollution 4.5 packs a day , experienced disappearance of RP. About 88% of non-tobacco users aged 4 years and older w x have detectable levels of cotinine in their blood 3 . In light of this widespread exposure, if a large proportion of young Ž . w x women as high as 20–30% experience RP 4 , then more than just hypothetical statements and case-by-case reports
Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection
Authors: Nicholas S. Heaton, Natasha Moshkina, Romain Fenouil, Thomas J. Gardner, Sebastian Aguirre, Priya S. Shah, Nan Zhao, Lara Manganaro, Judd F. Hultquist, Justine Noel, David Sachs, Jennifer Hamilton, Paul E. Leon, Amit Chawdury, Shashank Tripathi, Camilla Melegari, Laura Campisi, Rong Hai, Giorgi Metreveli, Andrea V. Gamarnik, Adolfo García-Sastre, Benjamin Greenbaum, Viviana Simon, Ana Fernandez-Sesma, Nevan J. Krogan, Lubbertus C.F. Mulder, Harm van Bakel, Domenico Tortorella, Jack Taunton, Peter Palese, Ivan Marazzi
Journal: Immunity (2016)
A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas.
Authors: H. Tilly, F. Morschhauser, G. A. Salles, O. Casasnovas, P. Feugier, T. J. Molina, C. Haioun, B. Coiffier
Journal: Journal of Clinical Oncology (2010)

TPS297 Background: R-CHOP has become the standard front-line treatment of most patients (pts) with B-cell lymphoma. Single drug studies of lenalidomide in relapsed/refractory lymphoma have demonstrated a significant activity in both indolent and aggressive lymphomas. Methods: This phase I study was designed to determine the recommended dose of lenalinomide when given in combination with R-CHOP-21 for patients with previously untreated B-cell lymphoma. Pts with previously untreated CD20+ B-cell lymphoma received R-CHOP (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, all on day 1, prednisone 100 mg/m2 days 1-5) given every 3 weeks for 6 cycles. Oral lenalidomide was administered on days 1-14 of each cycle, and was dose escalated at 5 mg per dose level according to a standard 3+3 design. Pegfilgrastim was administered on day 4 and oral aspirin (100 mg) was given daily during the treatment. Maximum tolerated dose (MTD) was determined by the number of dose limiting toxicities (DLT) during the first 2 cycles. DLT was defined as grade 3 or more nonhematological toxicity, grade 3 hematological toxicity lasting more than 7 days, or grade 4 hematological toxicity lasting more than 3 days. Fifteen pts have been enrolled to date (3 pts at 5 mg/day level, 3 at 10 mg, 3 at 15 mg and 6 at 20 mg). The 25 mg/day level is currently being evaluated. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Celgene, Roche Celgene Celgene
Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B
Authors: S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote, Ting-Tsung Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, J. Ma, S. Arterburn, S. Xiong, G. Currie, C. L. Brosgart
Journal: New England Journal of Medicine (2005)
Interim analysis of fluorodeoxyglucose uptake in patients with metastatic or recurrent gastric cancer treated with fluoropyrimidine based chemotherapy.
Authors: Suk-young Lee, Jaeseon Uh, Sang Cheul Oh
Journal: Journal of Clinical Oncology (2015)

44 Background: The role of 18 F-FDG PET/CT scanning in advanced gastric cancer (AGC) is still under investigation. We evaluated its prognostic role in patients with recurrent or metastatic AGC who received fluoropyrimidine based chemotherapy. Methods: Forty-six patients with metastatic or recurrent AGC who had the baseline and interim PET/CT scanning during the palliative chemotherapy were analyzed. The lesion with the highest SUVmax value among target lesions was determined to be a main target (SUVmax1), and interim SUVmax of the target lesion was measured after several cycles (4-12 cycles) of chemotherapy (SUVmax2). The formula calculating metabolic change follows: ΔSUVmax2-SUVmax1 (%) = (SUVmax2-SUVmax1)/SUVmax1 * 100 Results: Patients with SUVmax1 value &gt; 6 had a significantly higher response rate than those with the lower SUVmax1 (73.9% vs. 26.1%, p=0.036). SUVmax2 &lt; 5 was significantly associated with better overall survival (OS) (p=0.035) with univariate analysis. ΔSUVmax2- SUVmax1 &gt; -20% or appearance of new lesions with 18 F-FDG PET/CT scanning at interim analysis was significantly associated with worse OS (p=0.027). ΔSUVmax2- SUVmax1 &gt; -20% or new lesions (p=0.03) was the only factor significantly independently associated with OS using multivariate analysis (Table). Female (p=0.028), SUVmax2 &gt; 5 (p=0.002), and ΔSUVmax2-SUVmax1 value &gt; -20% (p=0.004) were significantly associated factors with worse progression free survival (PFS) using univariate analysis. Both SUVmax2 (p=0.028) and ΔSUVmax2-SUVmax1 value (p=0.043) were the significant factors associated with PFS using multivariate analysis. Conclusions: Analysis ofmetabolic change by interim PET/CT scanning is useful in predicting prognosis in patients with recurrent or metastatic AGC undergoing fluoropyrimidine based chemotherapy. [Table: see text]
Age related Epstein Barr virus associated B cell lymphoproliferative disorder in Peru
Authors: B. E. Beltran, D. Morales, P. Quiñones, A. Carrasco, E. Cotrina, A. I. Saez
Journal: Journal of Clinical Oncology (2008)

19514 Background: Age related Epstein Barr virus (EBV) associated B cell lymphoproliferative disorder is a recent new entity described in Japanese patients with diffuse large B cell lymphoma (DLBCL) and infection with EBV. It usually affects elderly patients with poor survival. Methods: In order to establish the correlation of EBV with DLBCL, we investigated the EBV status by RNA- in situ hybridization (ISH) in newly diagnosed nodal DLBCL.Between January 2002 and December 2004, seventy-four newly diagnosed nodal DLBCL patients were included in the analysis. Clinical data were reviewed retrospectively and patient’s biopsies were analyzed for the presence of EBV encoded RNA (EBER) by ISH and the immunohistochemical expression of BCL6, CD10 and MUM-1/IRF4 by tissue microarray (TMA) technique. Results: In this cohort the mean age was 66.1 years old (range 23–84) at diagnostic; male/female ratio 39/35; 46 patients (65.7%) with advanced stage (III/IV); 53 cases (71.6%) were of the non Germinal Center DLBCL type (non GC). This group was associated with a higher IPI than the Germinal Center DLBCL type (GC). Also there was a trend that the non GC type had a poorer overall survival than the GC type (p=0.171). Eleven cases of the cohort (14.9%) were identified as EBER-positive and were called as Age related EBV associated B cell lymphoproliferative disorder. Most of the cases EBER (+) were of the non GC group (10/11), showing a trend between EBER+ and non-GC DLBCL (OR=0.21, p=0.11 fisher 2-tails). EBER positive cases were associated with an advanced age (> 60 years), poorer status performance, more advanced stage, higher IPI risk group and poorer outcome to initial treatment. Overall survival in the EBER positive cases and negative were 1.1 vs. 15.5 months respectively (p=0.001). At the multivariable level de EBER status is an independent variable compared with the International Prognostic Index (IPI) (p=0.001) with a 3.2-fold (95% CI, 1.5 - 7.2) risk for death for positive cases Conclusions: Age related EBV associated B cell lymphoproliferative disorder is frequent between DLBCL in Peru. It was related to more advanced age, poor status performance, non-GC group and very short overall survival in comparison with DLBCL. New treatment strategies should be defined in this subgroup of poor prognostic. No significant financial relationships to disclose.
Multiple Sclerosis (Clinical and Pathogenetic Basis), by Ed C S Raine, H F McFarland, W W Tourtellotte
Authors: P K Newman
Journal: BMJ (1997)

Ed C S Raine, H F McFarland, W W Tourtellotte / Chapman and Hall, £125, pp 426 / ISBN 412 308908

Multiple sclerosis is one of the more common and most feared neurological diseases of young adults, with at least 50 000 cases in the United Kingdom and more than a million worldwide. Predominantly T cell mediated autoimmune mechanisms, triggered by earlier virus infection or other factors in those who are genetically predisposed, lead to destruction of myelin in the brain, optic nerves, and spinal cord. Research has yet to fully unravel the elusive pathogenesis or provide an effective …
Hand-assisted laparoscopic vs open colectomy in a rural healthcare center
Authors: R. U. Osarogiagbon, O. Ogbeide, R. George
Journal: Journal of Clinical Oncology (2007)

14587 Background: Complete surgical resection is a key component of curative therapy for colon cancer. Accurate pathologic staging requires examination of a sufficient number of lymph nodes in the resection specimen. Open colectomy (OC) is the traditional surgical technique, newer minimally-invasive laparoscopic techniques allow equivalent-quality cancer resection while reducing post-operative morbidity, but require longer operating time. Hand-assisted laparoscopic colectomy (HALC) may yield the benefits of laparoscopic colectomy while reducing operating time. The benefits of laparoscopic surgery reported in tertiary healthcare centers may not be achievable in non-tertiary care centers. We compared the operative experience of patients undergoing HALC to those who had OC at a rural veterans Hospital. Methods: Study design: Retrospective case-control study of consecutive patients undergoing HALC for colon cancer from April 2000 to September 2004 compared to patients who had OC. Patients with rectal and stage IV colon cancer were excluded. Reported variables were compared by the non-parametric Mann-Whitney U-test, all p-values are two-tailed. Results: Data is reported as HALC vs. OC. N= 39 in HALC cohort vs. 55 in OC. Median age: 72.1 vs 70.3 yrs (p 0.46). Location of tumors: right colon 62% vs 56%, left colon 2.5 vs 11%, sigmoid colon 36% vs 33. Stage: 0, 23% vs 11%; I 23% vs 23%; II 31% vs 36%; III 23% vs 31%. Median operating room time was 139 vs 137 minutes (p 0.94). 4 of 39 (10%) HALC procedures were converted to OC. Number of lymph nodes in resection specimen 12 vs 9 (p=0.043). Duration of hospitalization: 6 days vs 10 days (p=0.007). 5% of HALC patients were transfused vs 13% of OC patients. There were 3 cases of serious post-operative infection in the HALC group vs 9 in the OC cohort, 0 cases of wound dehiscence vs 3, 0 perioperative deaths vs 3. Overall, 8% of HALC patients developed severe post-operative surgical complications vs 22% of OC patients (p&lt;0.05). Conclusions: HALC is technically feasible in the non-tertiary care setting, with equivalent duration of surgery to OC, but significantly shorter duration of hospitalization. The quality of surgical resection, pathologic staging and rates of peri-operative morbidity and mortality are similar or slightly better with HALC. No significant financial relationships to disclose.
An assessment of cancer-related fatigue in patients (pts) with chemotherapy-induced anaemia (CIA) treated with darbepoetin alfa (DA): Comparison of two quality of life (QoL) questionnaires
Authors: G. Esquerdo, C. Llorca, J. Cervera, A. Juarez, D. Orts, A. Carrato
Journal: Journal of Clinical Oncology (2007)

19654 Background: CIA is often associated with debilitating fatigue and reduced QoL. DA can effectively treat CIA when administered once every 3 weeks (Q3W).This study aims to compare the psychometrics of the Functional Assessment of Cancer Therapy Fatigue Subscale (FACT-F) and The Fatigue Symptom Inventory (FSI) in CIA pts treated with DA Q3W. Methods: Longitudinal single- centre prospective study in adult pts with solid tumours undergoing chemotherapy (CT) and with mild to moderate cancer-related fatigue (CRF) (Visual Analogue Scale (VAS) =30 mm). Pts with haemoglobin (HB) levels &lt;11 g/dL were treated with DA 500 mcg Q3W. Key clinical parameters, FACT-F, and FSI measurements were collected at the beginning and end of the CT treatment period. Psychometric indicators for reliability and validity were calculated. Results: A preliminary analysis was conducted in 58 pts: mean age, 61.3 years (SD 12.3), 51.7% women, 25.9% with breast cancer, 91.4% ECOG 0–1, 69.0% IV stage, 63% had no prior CT. At baseline, the mean CRF score by VAS was 58.8 mm (SD 19.4) and the mean Hb was 10.2 g/dL (SD 0.7). Median CT duration was 15.1 weeks (range, 3.3 - 25.7) and all pts received DA treatment during CT (median duration of CT, 6.6 wks [range, 0 - 19]). The median number of DA doses administered was 3 (range, 1–7). The rate of hematopoietic response (Hb ≥ 12 g/dL or Hb rise from baseline ≥ 2 g/dL) was 69.0%. FACT-F and FIS scores improved by 5.6 and 13.0 points respectively during CT. Consistency (Cronbach alpha coefficient - CA) was high and similar for both questionnaires (FACT-F=0.98; FSI=0.97). Conclusions: Both the FACT-F and FIS QoL questionnaires measured a change in fatigue during the study with high and similar consistency. DA administered at a fixed dose of 500 mcg Q3W seems to be effective in clinical practice. No significant financial relationships to disclose.
Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM)
Authors: T. Gorlia, R. Stupp, E. A. Eisenhauer, R. O. Mirimanoff, M. J. Van Den Bent, K. Belanger, D. Lacombe, A. Allgeier
Journal: Journal of Clinical Oncology (2004)

9599 Background:In the EORTC 26981–22981/NCIC CE3 phase III trial, 573 pts with newly diagnosed GBM were randomized to receive radiotherapy (RT) or RT plus Temozolomide (results separately reported). In this analysis we evaluate clinical parameters as prognostic factors for survival. Methods:The Cox Proportional Hazard model was used to assess factors related to patients' characteristics (age, gender, WHO Performance Status (PS), Mini Mental State Examination (MMSE)), disease history (extent of resection, time between surgery and start of radiotherapy, administration of corticosteroids, baseline haematological and non-haematological toxicity status), tumor location (hemisphere and lobe). These factors were first screened by univariate technique and the hemisphere was the only variable that did not pass the 10% significance level.Results: In the multivariate analysis, poorer prognosis was associated with the extent of surgery (biopsy worse than partial or complete debulking) (p<0.0001), greater age (p=0.016), male gender (p=0.013), lower MMSE Score (p<0.0001), the administration of corticosteroids (p=0.012), tumor location in the frontal lobe (p=0.002) or tumor on more than one lobe (p=0.02). The time between surgery and start of radiotherapy, the baseline haematological and non-haematological toxicity status and the WHO PS status were not retained. Gender seems related to overall survival but probably because the proportion of male patients with a tumor on more than one lobe was significantly higher (p<0.0001).Conclusions: This analysis confirms the extent of surgery and age as major prognostic factors. MMSE has a better correlation to survival than WHO PS. The model will be validated with the bootstrap technique and on an independent data set. The results should be taken into consideration for future EORTC glioma trials. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough
T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease
Authors: Angela Vasaturo, Altuna Halilovic, Kalijn Bol, Dagmar Verweij, Willeke Blokx, Patricia Groenen, Han van Krieken, Johannes Textor, Jolanda de Vries, Carl Figdor
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Melanoma is a highly malignant melanocyte-derived tumor and its incidence is increasing at outstanding rate. Despite different types of immunotherapy became available for the treatment of melanoma, including adoptive T cell transfer, immune checkpoint blockade, and vaccines such
Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Authors: Paul G. Richardson, Andrew Spencer, Paul Cannell, Simon J. Harrison, Laurence Catley, Craig Underhill, Todd M. Zimmerman, Craig C. Hofmeister, Andrzej J Jakubowiak, Jacob P. Laubach, Michael A. Palladino, Angie M. Longenecker, Ana Lay, Sandra Wear, G. Kenneth Lloyd, Alison L. Hannah, Steve Reich, Matthew A. Spear, Kenneth C. Anderson
Journal: Blood (2011)